血清壳多糖酶3样蛋白1在慢性肝病进展中的临床应用价值

摘要/Abstract

摘要： 慢性肝病是由多种病因(如病毒感染、代谢异常、毒物损伤、免疫反应等)引起的肝脏持续性损伤过程。其病理学特征之一是肝脏纤维结缔组织的弥漫性增生,随着纤维化程度逐渐加重,最终可能发展为肝硬化甚至肝细胞癌。壳多糖酶3样蛋白1(chitinase 3-like 1,CHI3L1)是来源于肝巨噬细胞、活化肝星状细胞及多种间质细胞的分泌型糖蛋白,参与炎症反应、细胞外基质重塑与纤维化。研究显示,血清CHI3L1在肝纤维化、肝硬化、肝细胞癌进展过程中均有不同程度升高,且与肝硬化失代偿并发症风险及预后相关,在不同慢性肝病类型中均有一定的应用价值,可用于评估肝纤维化分期、动态监测治疗应答、以及不良预后预测。

关键词: 壳多糖酶3样蛋白1, 肝纤维化, 肝硬化, 肝细胞癌

雷林鸿, 赖长祥, 王方. 血清壳多糖酶3样蛋白1在慢性肝病进展中的临床应用价值[J]. 肝脏, 2026, 31(3): 449-453.

/ 推荐

参考文献

[1] Bedossa P, Carrat F. Liver biopsy: the best, not the gold standard[J]. J Hepatol, 2009, 50(1):1-3.
[2] European Association for the Study of the Liver. EASL Clinical Practice Guidelines on non-invasive tests for evaluation of liver disease severity and prognosis-2021 update[J]. J Hepatol, 2021, 75(3):659-689.
[3] 中国肝炎防治基金会, 中华医学会感染病学分会, 中华医学会肝病学分会和中国研究型医院学会肝病专业委员会. 瞬时弹性成像技术诊断肝纤维化专家共识(2018 年更新版)[J]. 中华肝脏病杂志, 2019, 27(3): 182-191.
[4] 桂红莲, 谢青, 王晖, 等. FibroTest-ActiTest对慢性乙型肝炎肝纤维化和炎症的诊断价值[J]. 中华肝脏病杂志, 2008, 16(12):897-901.
[5] Huang H, Wu T, Mao J, et al. CHI3L1 is a liver-enriched, noninvasive biomarker that can be used to stage and diagnose substantial hepatic fibrosis[J]. OMICS, 2015, 19(6):339-345.
[6] Johansen J S, Williamson M K, Rice J S, et al. Identification of proteins secreted by human osteoblastic cells in culture[J]. J Bone Miner Res, 1992, 7(5):501-512.
[7] Hakala B E, White C, Recklies A D. Human cartilage gp-39, a major secretory product of articular chondrocytes and synovial cells, is a mammalian member of a chitinase protein family[J]. J Biol Chem, 1993, 268(34):25803-25810.
[8] Recklies A D, White C, Ling H. The chitinase 3-like protein human cartilage glycoprotein 39 (HC-gp39) stimulates proliferation of human connective-tissue cells and activates both extracellular signal-regulated kinase- and protein kinase B-mediated signalling pathways[J]. Biochem J,2002,365(Pt 1):119-126.
[9] Renkema G H, Boot R G, Au F L, et al. Chitotriosidase, a chitinase, and the 39-kDa human cartilage glycoprotein, a chitin-binding lectin, are homologues of family 18 glycosyl hydrolases secreted by human macrophages[J]. Eur J Biochem,1998,251(1-2):504-509.
[10] Yeo I J, Lee C K, Han S B, et al. Roles of chitinase 3-like 1 in the development of cancer, neurodegenerative diseases, and inflammatory diseases[J]. Pharmacol Ther,2019,203:107394.
[11] Nishimura N, De Battista D, McGivern D R, et al. Chitinase 3-like 1 is a profibrogenic factor overexpressed in the aging liver and in patients with liver cirrhosis[J]. Proc Natl Acad Sci U S A,2021,118(17):e2019633118.
[12] Kumagai E, Mano Y, Yoshio S, et al. Serum YKL-40 as a marker of liver fibrosis in patients with non-alcoholic fatty liver disease[J]. Sci Rep,2016,6:35282.
[13] Wang S, Hu M, Qian Y, et al. CHI3L1 in the pathophysiology and diagnosis of liver diseases[J]. Biomed Pharmacother,2020,131:110680.
[14] Fan Y, Meng Y, Hu X, et al. Uncovering novel mechanisms of chitinase-3-like protein 1 in driving inflammation-associated cancers[J]. Cancer Cell Int,2024,24(1):268.
[15] Zhao H, Huang M, Jiang L. Potential roles and future perspectives of chitinase 3-like 1 in macrophage polarization and the development of diseases[J]. Int J Mol Sci,2023,24(22):16149.
[16] Qiu Q C, Wang L, Jin S S, et al. CHI3L1 promotes tumor progression by activating TGF-β signaling pathway in hepatocellular carcinoma[J]. Sci Rep,2018,8(1):15029.
[17] Yu J E, Yeo I J, Han S B, et al. Significance of chitinase-3-like protein 1 in the pathogenesis of inflammatory diseases and cancer[J]. Exp Mol Med,2024,56(1):1-18.
[18] Hu X, Liu W, Liu J, et al. Research advances in serum chitinase-3-like protein 1 in liver fibrosis[J]. Front Med (Lausanne),2024,11:1372434.
[19] Kim A D, Kui L, Kaufmann B, et al. Myeloid-specific deletion of chitinase-3-like 1 protein ameliorates murine diet-induced steatohepatitis progression[J]. J Mol Med (Berl),2023,101(7):813-828.
[20] 尤红, 王福生, 李太生, 等. 慢性乙型肝炎防治指南(2022年版)[J]. 实用肝脏病杂志,2023,26(03):457-478.
[21] Jiang Z, Wang S, Jin J, et al. The clinical significance of serum chitinase 3-like 1 in hepatitis B-related chronic liver diseases[J]. J Clin Lab Anal,2020,34(5):e23200.
[22] Lebensztejn D M, Skiba E, Werpachowska I, et al. Serum level of YKL-40 does not predict advanced liver fibrosis in children with chronic hepatitis B[J]. Adv Med Sci,2007,52:120-124.
[23] Rath T, Roderfeld M, Güler C, et al. YKL-40 and transient elastography, a powerful team to assess hepatic fibrosis[J]. Scand J Gastroenterol,2011,46(11):1369-1380.
[24] Schiavon L L, Carvalho-Filho R J, Narciso-Schiavon J L, et al. YKL-40 and hyaluronic acid (HA) as noninvasive markers of liver fibrosis in kidney transplant patients with HCV chronic infection[J]. Scand J Gastroenterol,2010,45(5):615-622.
[25] Harrison S A, Ratziu V, Boursier J, et al. A blood-based biomarker panel (NIS4) for non-invasive diagnosis of non-alcoholic steatohepatitis and liver fibrosis: a prospective derivation and global validation study[J]. Lancet Gastroenterol Hepatol,2020,5(11):970-985.
[26] Harrison S A, Ratziu V, Magnanensi J, et al. NIS2+^TM, an optimisation of the blood-based biomarker NIS4R technology for the detection of at-risk NASH: a prospective derivation and validation study[J]. J Hepatol,2023,79(3):758-767.
[27] Sakamoto Y, Yoshio S, Doi H, et al. Serum soluble sialic acid-binding immunoglobulin-like lectin-7 concentration as an indicator of liver macrophage activation and advanced fibrosis in patients with non-alcoholic fatty liver disease[J]. Hepatol Res,2020,50(4):466-477.
[28] Wang L, Liu T, Zhou J, et al. Changes in serum chitinase 3-like 1 levels correlate with changes in liver fibrosis measured by two established quantitative methods in chronic hepatitis B patients following antiviral therapy[J]. Hepatol Res,2018,48(3):E283-E290.
[29] Kang Q, Liu J X, Tan N, et al. Diagnostic value of novel hepatic fibrosis markers in assessing cirrhosis in patients with chronic hepatitis C[J]. Zhonghua Gan Zang Bing Za Zhi,2023,31(1):56-64.
[30] European Association for the Study of the Liver (EASL); European Association for the Study of Diabetes (EASD); European Association for the Study of Obesity (EASO). EASL-EASD-EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD)[J]. J Hepatol,2024,81(3):492-542.
[31] Hempen M, Kopp H P, Elhenicky M, et al. YKL-40 is elevated in morbidly obese patients and declines after weight loss[J]. Obes Surg,2009,19(11):1557-1563.
[32] Wu X N, Xue F, Zhang N, et al. Global burden of liver cirrhosis and other chronic liver diseases caused by specific etiologies from 1990 to 2019[J]. BMC Public Health,2024,24(1):363.
[33] 杨航, 赵黎莉, 韩萍, 等. 血清壳多糖酶3样蛋白1(CHI3L1)对肝硬化患者发生失代偿事件风险的预测价值[J]. 临床肝胆病杂志,2023,39(7):1578-1585.
[34] Hanno A, EL-Kady AM, Bedewy E, et al. Diagnostic validity of serum YKL-40 as a non-invasive diagnostic marker of oesophageal varices in cirrhotic hepatitis C virus patients[J]. Egyptian Liver Journal,2022,12(1):45.
[35] Wang S, Chen S, Jin M, et al. Diagnostic and prognostic value of serum Chitinase 3-like protein 1 in hepatocellular carcinoma[J]. J Clin Lab Anal,2022,36(2):e24234.
[36] Pan J J, Ge Y S, Xu G L, et al. The expression of chitinase 3-like 1: a novel prognostic predictor for hepatocellular carcinoma[J]. J Cancer Res Clin Oncol,2013,139(6):1043-1054.
[37] Zhu C B, Chen L L, Tian J J, et al. Elevated serum YKL-40 level predicts poor prognosis in hepatocellular carcinoma after surgery[J]. Ann Surg Oncol,2012,19(3):817-825.
[38] Zhu C B, Wang C, Chen L L, et al. Serum YKL-40 independently predicts outcome after transcatheter arterial chemoembolization of hepatocellular carcinoma[J]. PLoS One,2012,7(9):e44648.
[39] Bojesen S E, Johansen J S, Nordestgaard B G. Plasma YKL-40 levels in healthy subjects from the general population[J]. Clin Chim Acta,2011,412(9-10):709-712.
[40] Yan L, Deng Y, Zhou J, et al. Serum YKL-40 as a biomarker for liver fibrosis in chronic hepatitis B patients with normal and mildly elevated ALT[J]. Infection,2018,46(3):385-393.
[41] Nøjgaard C, Johansen J S, Christensen E, et al. Serum levels of YKL-40 and PIIINP as prognostic markers in patients with alcoholic liver disease[J]. J Hepatol,2003,39(2):179-186.
[42] Johansen J S, Stoltenberg M, Hansen M, et al. Serum YKL-40 concentrations in patients with rheumatoid arthritis: relation to disease activity[J]. Rheumatology (Oxford),1999,38(7):618-626.
[43] Luo W, Zhang L, Sheng L, et al. Increased levels of YKL-40 in patients with diabetes mellitus: a systematic review and meta-analysis[J]. Diabetol Metab Syndr,2021,13:6.
[44] Higashiyama M, Tomita K, Sugihara N, et al. Chitinase 3-like 1 deficiency ameliorates liver fibrosis by promoting hepatic macrophage apoptosis[J]. Hepatol Res,2019,49(11):1316-1328.
[45] Shan Z, Li L, Atkins C L, et al. Chitinase 3-like-1 contributes to acetaminophen-induced liver injury by promoting hepatic platelet recruitment[J]. Elife,2021,10:e68571.
[46] Li L, Wen Y, Wrapp D, et al. A novel humanized Chi3l1 blocking antibody attenuates acetaminophen-induced liver injury in mice[J]. Antib Ther,2022,6(1):1-12.